Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine

Xiaoyi Zhang, 1, 2 Yixin Zhang, 1, 2 Yaonan Wang, 1, 2 Jianhui Wu, 1, 2 Haiyan Chen, 1, 2 Ming Zhao, 1–3 Shiqi Peng 1, 2 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, B...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhang X, Zhang Y, Wang Y, Wu J, Chen H, Zhao M, Peng S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/0b71e198e060471ab3a6f1dd26df725b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0b71e198e060471ab3a6f1dd26df725b
record_format dspace
spelling oai:doaj.org-article:0b71e198e060471ab3a6f1dd26df725b2021-12-02T08:18:59ZModifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine1178-2013https://doaj.org/article/0b71e198e060471ab3a6f1dd26df725b2020-01-01T00:00:00Zhttps://www.dovepress.com/modifying-icca-with-trp-phe-phe-to-enhance-in-vivo-activity-and-form-n-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Xiaoyi Zhang, 1, 2 Yixin Zhang, 1, 2 Yaonan Wang, 1, 2 Jianhui Wu, 1, 2 Haiyan Chen, 1, 2 Ming Zhao, 1–3 Shiqi Peng 1, 2 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China; 2Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China; 3Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100026, People’s Republic of ChinaCorrespondence: Shiqi Peng; Ming ZhaoDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, No. 10, Youanmenwaixitoutiao, Fengtai District, Beijing 100069, People’s Republic of ChinaTel +86 10 8391 1528; +86 10 8391 1535Fax +86 10 8391 1528; +86 10 8391 1533Email sqpeng@bjmu.edu.cn; maozhao@126.comBackground: 1-(4-isopropylphenyl)-β-carboline-3-carboxylic acid (ICCA) was modified by Trp-Phe-Phe to form 1-(4-isopropylphenyl)-β-carboline-3-carbonyl-Trp-Phe-Phe (ICCA-WFF).Purpose: The object of preparing ICCA-WFF was to enhance the in vivo efficacy of ICCA, to explore the possible targeting action, and to visualize the nano-feature.Methods: The advantages of ICCA-WFF over ICCA were demonstrated by a series of in vivo assays, such as anti-tumor assay, anti-arterial thrombosis assay, anti-venous thrombosis assay, P-selectin expression assay, and GPIIb/IIIa expression assay. The nano-features of ICCA-WFF were visualized by TEM, SEM and AFM images. The thrombus targeting and tumor-targeting actions were evidenced by FT-MS spectrum analysis.Results: The minimal effective dose of ICCA-WFF slowing tumor growth and inhibiting thrombosis was 10-fold lower than that of ICCA. ICCA-WFF, but not ICCA, formed nano-particles capable of safe delivery in blood circulation. In vivo ICCA-WFF, but not ICCA, can target thrombus and tumor. In thrombus and tumor, ICCA-WFF released Trp-Phe-Phe and/or ICCA.Conclusion: Modifying ICCA with Trp-Phe-Phe successfully enhanced the anti-tumor activity, improved the anti-thrombotic action, formed nano-particles, targeted tumor tissue and thrombus, and provided an oligopeptide modification strategy for heterocyclic compounds.Keywords: ICCA, modification, Trp-Phe-Phe, anti-tumor, thrombus targeting, release, toxicity, nano-speciesZhang XZhang YWang YWu JChen HZhao MPeng SDove Medical Pressarticleiccamodificationtrp-phe-pheanti-tumorthrombus targetingreleasetoxicitynano-speciesMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 465-481 (2020)
institution DOAJ
collection DOAJ
language EN
topic icca
modification
trp-phe-phe
anti-tumor
thrombus targeting
release
toxicity
nano-species
Medicine (General)
R5-920
spellingShingle icca
modification
trp-phe-phe
anti-tumor
thrombus targeting
release
toxicity
nano-species
Medicine (General)
R5-920
Zhang X
Zhang Y
Wang Y
Wu J
Chen H
Zhao M
Peng S
Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine
description Xiaoyi Zhang, 1, 2 Yixin Zhang, 1, 2 Yaonan Wang, 1, 2 Jianhui Wu, 1, 2 Haiyan Chen, 1, 2 Ming Zhao, 1–3 Shiqi Peng 1, 2 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China; 2Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, People’s Republic of China; 3Beijing Laboratory of Biomedical Materials and Key Laboratory of Biomedical Materials of Natural Macromolecules, Department of Biomaterials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100026, People’s Republic of ChinaCorrespondence: Shiqi Peng; Ming ZhaoDepartment of Medicinal Chemistry, School of Pharmaceutical Sciences, Capital Medical University, No. 10, Youanmenwaixitoutiao, Fengtai District, Beijing 100069, People’s Republic of ChinaTel +86 10 8391 1528; +86 10 8391 1535Fax +86 10 8391 1528; +86 10 8391 1533Email sqpeng@bjmu.edu.cn; maozhao@126.comBackground: 1-(4-isopropylphenyl)-β-carboline-3-carboxylic acid (ICCA) was modified by Trp-Phe-Phe to form 1-(4-isopropylphenyl)-β-carboline-3-carbonyl-Trp-Phe-Phe (ICCA-WFF).Purpose: The object of preparing ICCA-WFF was to enhance the in vivo efficacy of ICCA, to explore the possible targeting action, and to visualize the nano-feature.Methods: The advantages of ICCA-WFF over ICCA were demonstrated by a series of in vivo assays, such as anti-tumor assay, anti-arterial thrombosis assay, anti-venous thrombosis assay, P-selectin expression assay, and GPIIb/IIIa expression assay. The nano-features of ICCA-WFF were visualized by TEM, SEM and AFM images. The thrombus targeting and tumor-targeting actions were evidenced by FT-MS spectrum analysis.Results: The minimal effective dose of ICCA-WFF slowing tumor growth and inhibiting thrombosis was 10-fold lower than that of ICCA. ICCA-WFF, but not ICCA, formed nano-particles capable of safe delivery in blood circulation. In vivo ICCA-WFF, but not ICCA, can target thrombus and tumor. In thrombus and tumor, ICCA-WFF released Trp-Phe-Phe and/or ICCA.Conclusion: Modifying ICCA with Trp-Phe-Phe successfully enhanced the anti-tumor activity, improved the anti-thrombotic action, formed nano-particles, targeted tumor tissue and thrombus, and provided an oligopeptide modification strategy for heterocyclic compounds.Keywords: ICCA, modification, Trp-Phe-Phe, anti-tumor, thrombus targeting, release, toxicity, nano-species
format article
author Zhang X
Zhang Y
Wang Y
Wu J
Chen H
Zhao M
Peng S
author_facet Zhang X
Zhang Y
Wang Y
Wu J
Chen H
Zhao M
Peng S
author_sort Zhang X
title Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine
title_short Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine
title_full Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine
title_fullStr Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine
title_full_unstemmed Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine
title_sort modifying icca with trp-phe-phe to enhance in vivo activity and form nano-medicine
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/0b71e198e060471ab3a6f1dd26df725b
work_keys_str_mv AT zhangx modifyingiccawithtrpphephetoenhanceinvivoactivityandformnanomedicine
AT zhangy modifyingiccawithtrpphephetoenhanceinvivoactivityandformnanomedicine
AT wangy modifyingiccawithtrpphephetoenhanceinvivoactivityandformnanomedicine
AT wuj modifyingiccawithtrpphephetoenhanceinvivoactivityandformnanomedicine
AT chenh modifyingiccawithtrpphephetoenhanceinvivoactivityandformnanomedicine
AT zhaom modifyingiccawithtrpphephetoenhanceinvivoactivityandformnanomedicine
AT pengs modifyingiccawithtrpphephetoenhanceinvivoactivityandformnanomedicine
_version_ 1718398525002219520